Mark J. Levis
马克·莱维斯
MD, PhD
Professor of Oncology, Director of Hematologic Malignancies Program肿瘤学教授，血液恶性肿瘤项目主任
👥Biography 个人简介
Dr. Mark Levis is the foremost authority on FLT3-mutated AML, having co-developed and led trials for midostaurin and quizartinib. His laboratory and clinical research transformed FLT3 from a prognostic marker to an actionable therapeutic target, establishing targeted therapy as standard of care in FLT3-mutated AML.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FLT3 Inhibitor Development
Led landmark RATIFY trial establishing midostaurin plus chemotherapy as the first approved targeted therapy for FLT3-mutated AML, and the QuANTUM-R trial showing quizartinib survival benefit in relapsed FLT3-ITD AML.
FLT3 Resistance Mechanisms
Characterized F691L and D835 resistance mutations to first-generation FLT3 inhibitors, guiding development of next-generation agents and combination strategies to overcome resistance.
Representative Works 代表性著作
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with FLT3 Mutation
New England Journal of Medicine (2017)
RATIFY trial demonstrating midostaurin plus standard chemotherapy significantly improved OS in newly diagnosed FLT3-mutated AML patients.
Quizartinib versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD AML
Lancet Oncology (2021)
QuANTUM-R trial showing quizartinib improved survival versus salvage chemo in relapsed FLT3-ITD AML.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Elihu Estey
Fred Hutchinson Cancer Center
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Naval Daver
The University of Texas MD Anderson Cancer Center
Courtney DiNardo
The University of Texas MD Anderson Cancer Center
关注 马克·莱维斯 的研究动态
Follow Mark J. Levis's research updates
留下邮箱，当我们发布与 Mark J. Levis（Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment